LDI Senior Fellows Get $4.9 Million Grant for Implementation Science and Behavioral Economics in Cancer Care
Do Physician Incentives Increase Patient Medication Adherence?
Edward Kong, John Beshears, David Laibson, Brigitte Madrian, Kevin Volpp, George Loewenstein, Jonathan Kolstad, James J. Choi
Abstract [from journal]
Objective: To test the effectiveness of physician incentives for increasing patient medication adherence in three drug classes: diabetes medication, antihypertensives, and statins.
Data sources: Pharmacy and medical claims from a large Medicare Advantage Prescription Drug Plan from January 2011 to December 2012.
Study design: We conducted a randomized experiment (911 primary care practices and 8,935 nonadherent patients) to test the effect of paying physicians for
...Is The Threat of COVID Vaccine Hesitancy Getting Enough Attention?
COVID-19 and Cardiovascular Telemedicine Care
While COVID-19 has created unprecedented challenges for the U.S. health care system, it has also accelerated innovation, including the use and adoption of telemedicine.
CHERISH Studies on Substance Use Treatment Economics Get New 5-Year, $8 Million Grant
COVID-19 Boosts Deployment of Technology-Enabled Remote Health Care Delivery Systems
Penn LDI Team Wins American Society of Transplantation 2020 Innovation Award
Mary Naylor Transitional Care Model to Get $6 Million Evaluation
Philadelphia/Penn Collaboration Expands Use of Evidence-Based Mental Health Treatments
Hospital Financial Incentives to Improve Care After Opioid Overdose
Two patients are treated for opioid overdose at two different hospitals, just a few miles apart. The first hospital provides life-saving treatment to reverse the overdose and watches the patient for an hour, discharging them when deemed “medically stable.” The second hospital also provides life-saving treatment but then offers counseling, medication to prevent recurrent overdose and treat opioid withdrawal, and assistance navigating to outpatient treatment for the next day.
National Trends in Utilization and 1-Year Outcomes with Transplantation of HCV-Viremic Kidneys
Vishnu S. Potluri, David S. Goldberg, Sumit Mohan, Roy D. Bloom, Deirdre Sawinski, Peter L. Abt, Emily A. Blumberg, Chirag R. Parikh, James Sharpe, K. Rajender Reddy, Miklos Z. Molnar, Meghan Sise, Peter P. Reese
Abstract [from journal]
Background: Recent pilot trials have demonstrated the safety of transplanting HCV-viremic kidneys into HCV-seronegative recipients. However, it remains unclear if allograft function is impacted by donor HCV-viremia or recipient HCV-serostatus.
Methods: We used national United States registry data to examine trends in HCV-viremic kidney use between 4/1/2015 and 3/31/2019. We applied advanced matching methods to compare eGFR for similar kidneys transplanted into highly similar recipients of kidney transplants.
...